A high notch pathway activation predicts response to c secretase inhibitors in proneural subtype of glioma tumor-initiating cells

Stem Cells

Volumn 32, Issue 1, 2014, Pages 301-312

  Saito, Norihiko ^a   Fu, Jun ^a   Zheng, Siyuan ^b   Yao, Jun ^a   Wang, Shuzhen ^a   Liu, Diane D ^b   Yuan, Ying ^b   Sulman, Erik P ^b   Lang, Frederick F ^b   Colman, Howard ^a   Verhaak, Roel G ^b   Yung, W K Alfred ^a   Koul, Dimpy ^a  

^a Brain Tumor Center   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

C Secretase inhibitors; Glioma; Notch activation; Proneural genes

Indexed keywords

AVAGACESTAT; DLL 3 PROTEIN; GAMMA SECRETASE; JAG2 PROTEIN; MAML1 PROTEIN; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; PROTEIN; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GLIOMA; GLIOMA TUMOR INITIATING CELL; HUMAN; HUMAN CELL; IC 50; MOUSE; MOUSE MODEL; NERVE CELL DIFFERENTIATION; NONHUMAN; PATIENT SELECTION; PROTEIN EXPRESSION; SURVIVAL TIME; TIME; TREATMENT RESPONSE; TUMOR GENE;

GLIOMA; NOTCH ACTIVATION; PRONEURAL GENES; Γ SECRETASE INHIBITORS;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GLIOMA; HUMANS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PROTEASE INHIBITORS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891810705     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1528     Document Type: Article

References (48)

1. Chang SM, Theodosopoulos P, Lamborn K et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer 2004; 100:605-611.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
3. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
4. Purow B, Schiff D. Advances in the genetics of glioblastoma: Are we reaching critical mass? Nat Rev Neurol 2009;5:419-426.
5. Goodwin CR, Laterra J. Neuro-oncology: Unmasking the multiforme in glioblastoma. Nat Rev Neurol 2010;6:304-305.
6. MacDonald TJ, Brown KM, LaFleur B et al. Expression profiling of medulloblastoma PDGFRA and the AS/MAPK pathway. Nat Genet 2001;29:143-152.
7. Nagarajan RP, Costello JF. Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics 2009;6:436-446.
8. Robinson JP, VanBrocklin MW, Guilbeault AR et al. Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene 2010;29:335-344.
9. Mladkova N, Chakravarti A. Molecular profiling in glioblastoma: Prelude to personalized treatment. Curr Oncol Rep 2009;11:53-61.
10. Colman H, Zhang L, Sulman EP et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol 2010;12:49-57.
11. Schadt EE, Friend SH, Shaywitz DA. A network view of disease and compound screening. Nat Rev Drug Discov 2009;8:286-295.
12. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
13. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004;101:781-786.
14. Ikushima H, Todo T, Ino Y et al. Gliomainitiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. J Biol Chem 2010;286:41434-41441.
15. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
16. Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD1331 cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
17. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17: 98-110.
18. Kopan R, Ilagan MX. The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 2009;137:216-233.
19. Fortini ME. Notch signaling: The core pathway and its posttranslational regulation. Dev Cell 2009;16:633-647.
20. Kageyama R, Ohtsuka T. The Notch-Hes pathway in mammalian neural development. Cell Res 1999;9:179-188.
21. Kageyama R, Ohtsuka T, Hatakeyama J et al. Roles of bHLH genes in neural stem cell differentiation. Exp Cell Res 2005;306: 343-348.
22. Hatakeyama J, Sakamoto S, Kageyama R. Hes1 and Hes5 regulate the development of the cranial and spinal nerve systems. Dev Neurosci 2006;28:92-101.
23. Reedijk M, Odorcic S, Zhang H et al. Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol 2008;33:1223-1229.
24. Liu S, Breit S, Danckwardt S et al. Downregulation of Notch signaling by gammasecretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Ann Hematol 2009;88:613-621.
25. Watters JW, Cheng C, Majumder PK et al. De novo discovery of a gammasecretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res 2009;69:8949-8957.
26. Cuevas IC, Slocum AL, Jun P et al. Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 2005;65:5070-5075.
27. Yokota N, Mainprize TG, Taylor MD et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 2004;23:3444-3453.
28. Kanamori M, Kawaguchi T, Nigro JM et al. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg 2007;106:417-427.
29. Purow BW, Haque RM, Noel MW et al. Expression of Notch-1 and its ligands, Deltalike-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005; 65:2353-2363.
30. Zhu TS, Costello MA, Talsma CE et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res 2011;71:6061-6072.
31. Jiang X, Xing H, Kim TM et al. Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity. Stem Cells 2012;30:1313-1326.
32. Wang J, Wakeman TP, Lathia JD et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010;28:17-28.
33. Fan X, Khaki L, Zhu TS et al. Notch pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010;28:5-16.
34. Gilbert CA, Daou MC, Moser RP et al. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 2010;70:6870-6879.
35. Bhat KP, Salazar KL, Balasubramaniyan V et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011;25:2594-2609.
36. Subramanian A, Tamayo P, Mootha VK et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-15550.
37. Kanehisa M, Goto S, Sato Y et al. KEGG for integration and interpretation of largescale molecular data sets. Nucleic Acids Res 2012;40:D109-114.
38. Bengtsson H, Jönsson G, Vallon-Christersson J. Calibration and assessment of channel-specific biases in microarray data with extended dynamical range. BMC Bioinformatics 2004;5:177.
39. Barbie DA, Tamayo P, Boehm JS et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-112.
40. Koul D, Jasser SA, Lu Y et al. Motif analysis of the tumor suppressor gene MMAC/ PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 2002;21:2357-2364.
41. Liu JL, Sheng X, Hortobagyi ZK et al. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 2005;25:6211-6224.
42. Bao S, Wu Q, Li Z et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008;68:6043-6048.
43. Lal S, Lacroix M, Tofilon P et al. An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 2000;92:326-333.
44. Cooper LA, Gutman DA, Long Q et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 2010;5:e12548.
45. Tso CL, Freije WA, Day A et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 2006;66:159-167.
46. Katoh M, Katoh M. Integrative genomic analyses on HES/HEY family: Notchindependent HES1, HES3 transcription in undifferentiated ES cells, and notchdependent HES1, HES5, HEY1, HEY2, Heyl transcription in fetal tissues, adult tissues, or cancer. Int J Oncol 2007;31:461-466.
47. Hoey T, Yen WC, Axelrod F et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-177.
48. Fan X, Mikolaenko I, Elhassan I et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004;64:7787-7793.